Table 1.
Sample Attributes of Patients Who Harbor Germline TP53 Mutations and Those With TP53 Wild Type in the Initial and Validation Cohorts
| Cohort | Mutation Carrier | Wild Type |
|---|---|---|
| Initial | ||
| No. of samples | 72 | 111 |
| Mean age, years (range) | 12.54 (0.5-47.0) | 15.46 (0.03-60) |
| Male:female sex* | 34:33 | 46:59 |
| Diagnosis | ||
| Adrenocortical carcinoma | 22 | 24 |
| Brain tumor | 19 | 20 |
| Choroid plexus carcinoma | 9 | 7 |
| Astrocytoma/glioblastoma | 7 | 10 |
| Primitive neuroectodermal tumor | 3 | 4 |
| Breast | 10 | 10 |
| Sarcoma | 14 | 24 |
| Rhabdomyosarcoma | 12 | 21 |
| Other (myofibroblastic sarcoma, leiomyosarcoma) | 2 | 3 |
| Papillary thyroid carcinoma | 0 | 3 |
| Multiple primary malignancies | 24 | 1 |
| Unaffected | 17 | 30 |
| Validation | ||
| No. of samples | 30 | 46 |
| Mean age, years (range) | 18.03 (2-49.0) | 29 (0.83-60.0) |
| Male:female sex* | 8:16 | 12:33 |
| Tumor validation (choroid plexus carcinomas) | ||
| No. of samples | 24 | 18 |
| Mean age, years (range) | 1.22 (0.39-6.9) | 3.35 (0.01-16.53) |
| Male:female sex | 18:6 | 10:8 |
*
Where reported.